Drug Trial Radar · NCT05544227
Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Jul 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Feb 1, 2023
Primary completion
Dec 10, 2024
Study completion Jun 1, 2025
Sponsor
- Lead sponsor
- Williams Cancer FoundationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Syncromune, Inc.
- First posted
- Sep 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
SV-102 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.
Conditions
- Metastatic Castration-resistant Prostate Cancer
Interventions
SV-102Drug
SV-102 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immunopharmacologic effects.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.Time frame: Baseline through 30 days after end-of-treatment
- Number of participants with deathsTime frame: Baseline through 30 days after end-of-treatment
- Number of participants with treatment-emergent SAEs and AEsTime frame: Baseline through 30 days after end-of-treatment
- Assessment of laboratory values.Time frame: Baseline through 30 days after end-of-treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital Diomed
Mexico City, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.